141 related articles for article (PubMed ID: 28377059)
1. Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitors.
Ramachandran SA; Jadhavar PS; Miglani SK; Singh MP; Kalane DP; Agarwal AK; Sathe BD; Mukherjee K; Gupta A; Haldar S; Raja M; Singh S; Pham SM; Chakravarty S; Quinn K; Belmar S; Alfaro IE; Higgs C; Bernales S; Herrera FJ; Rai R
Bioorg Med Chem Lett; 2017 May; 27(10):2153-2160. PubMed ID: 28377059
[TBL] [Abstract][Full Text] [Related]
2. Identification, synthesis and evaluation of CSF1R inhibitors using fragment based drug design.
Machiraju PK; Yedla P; Gubbala SP; Bohari T; Abdul JKV; Xu S; Patel R; Chittireddy VRR; Boppana K; Jagarlapudi SARP; Neamati N; Syed R; Amanchy R
Comput Biol Chem; 2019 Jun; 80():374-383. PubMed ID: 31103918
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent colony-stimulating factor 1 receptor inhibitors by replacement of hinge-binder moieties.
Lee JW; Park J; Kim J; Kim J; Choi C; Min KH
Eur J Med Chem; 2021 Apr; 216():113298. PubMed ID: 33689933
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Structure-Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5- d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors.
Xun Q; Zhang Z; Luo J; Tong L; Huang M; Wang Z; Zou J; Liu Y; Xu Y; Xie H; Tu ZC; Lu X; Ding K
J Med Chem; 2018 Mar; 61(6):2353-2371. PubMed ID: 29499108
[TBL] [Abstract][Full Text] [Related]
6. Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.
Czako B; Marszalek JR; Burke JP; Mandal P; Leonard PG; Cross JB; Mseeh F; Jiang Y; Chang EQ; Suzuki E; Kovacs JJ; Feng N; Gera S; Harris AL; Liu Z; Mullinax RA; Pang J; Parker CA; Spencer ND; Yu SS; Wu Q; Tremblay MR; Mikule K; Wilcoxen K; Heffernan TP; Draetta GF; Jones P
J Med Chem; 2020 Sep; 63(17):9888-9911. PubMed ID: 32787110
[TBL] [Abstract][Full Text] [Related]
7. First-in-class DAPK1/CSF1R dual inhibitors: Discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidin-5-yl)benzamide as a potential anti-tauopathies agent.
Farag AK; Hassan AHE; Jeong H; Kwon Y; Choi JG; Oh MS; Park KD; Kim YK; Roh EJ
Eur J Med Chem; 2019 Jan; 162():161-175. PubMed ID: 30445265
[TBL] [Abstract][Full Text] [Related]
8. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.
Wen J; Wang S; Guo R; Liu D
Eur J Med Chem; 2023 Jan; 245(Pt 1):114884. PubMed ID: 36335744
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of (R)-1-arylsulfonylpiperidine-2-carboxamides as 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
Xia G; Liu L; Liu H; Yu J; Xu Z; Chen Q; Ma C; Li P; Xiong B; Liu X; Shen J
ChemMedChem; 2013 Apr; 8(4):577-81. PubMed ID: 23471829
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Properties of JTE-952, an Orally Available and Selective Colony Stimulating Factor 1 Receptor Kinase Inhibitor.
Uesato N; Miyagawa N; Inagaki K; Kakefuda R; Kitagawa Y; Matsuo Y; Yamaguchi T; Hata T; Ikegashira K; Matsushita M
Biol Pharm Bull; 2020; 43(2):325-333. PubMed ID: 32009119
[TBL] [Abstract][Full Text] [Related]
11. Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R.
Liu YQ; Wang YN; Lu XY; Tong LJ; Li Y; Zhang T; Xun QJ; Feng F; Chen YZ; Su Y; Shen YY; Chen Y; Geng MY; Ding K; Li YL; Xie H; Ding J
Acta Pharmacol Sin; 2018 Nov; 39(11):1768-1776. PubMed ID: 29968849
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology.
Olmos-Alonso A; Schetters ST; Sri S; Askew K; Mancuso R; Vargas-Caballero M; Holscher C; Perry VH; Gomez-Nicola D
Brain; 2016 Mar; 139(Pt 3):891-907. PubMed ID: 26747862
[TBL] [Abstract][Full Text] [Related]
13. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment.
O'Brien SA; Orf J; Skrzypczynska KM; Tan H; Kim J; DeVoss J; Belmontes B; Egen JG
Cancer Immunol Immunother; 2021 Aug; 70(8):2401-2410. PubMed ID: 33511454
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of HIV-1 attachment. Part 7: indole-7-carboxamides as potent and orally bioavailable antiviral agents.
Yeung KS; Qiu Z; Xue Q; Fang H; Yang Z; Zadjura L; D'Arienzo CJ; Eggers BJ; Riccardi K; Shi PY; Gong YF; Browning MR; Gao Q; Hansel S; Santone K; Lin PF; Meanwell NA; Kadow JF
Bioorg Med Chem Lett; 2013 Jan; 23(1):198-202. PubMed ID: 23200252
[TBL] [Abstract][Full Text] [Related]
15. Role of CSF1R 550th-tryptophan in kusunokinin and CSF1R inhibitor binding and ligand-induced structural effect.
Chompunud Na Ayudhya C; Graidist P; Tipmanee V
Sci Rep; 2024 May; 14(1):12531. PubMed ID: 38822100
[TBL] [Abstract][Full Text] [Related]
16. Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.
Jonckers TH; Rouan MC; Haché G; Schepens W; Hallenberger S; Baumeister J; Sasaki JC
Bioorg Med Chem Lett; 2012 Aug; 22(15):4998-5002. PubMed ID: 22765892
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors.
Liang X; Wang C; Wang B; Liu J; Qi S; Wang A; Liu Q; Deng M; Wang L; Liu J; Liu Q
Eur J Med Chem; 2022 Dec; 243():114782. PubMed ID: 36179404
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ).
Mata G; Miles DH; Drew SL; Fournier J; Lawson KV; Mailyan AK; Sharif EU; Yan X; Beatty JW; Banuelos J; Chen J; Ginn E; Chen A; Gerrick KY; Pham AT; Wong K; Soni D; Dhanota P; Shaqfeh SG; Meleza C; Narasappa N; Singh H; Zhao X; Jin L; Schindler U; Walters MJ; Young SW; Walker NP; Leleti MR; Powers JP; Jeffrey JL
J Med Chem; 2022 Jan; 65(2):1418-1444. PubMed ID: 34672584
[TBL] [Abstract][Full Text] [Related]
19. Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kβ inhibitors.
Certal V; Halley F; Virone-Oddos A; Filoche-Rommé B; Carry JC; Gruss-Leleu F; Bertin L; Guizani H; Pilorge F; Richepin P; Karlsson A; Charrier V; Abecassis PY; Vincent L; Nicolas JP; Lengauer C; Garcia-Echeverria C; Schio L
Bioorg Med Chem Lett; 2014 Mar; 24(6):1506-10. PubMed ID: 24560540
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators.
Pettersson M; Johnson DS; Subramanyam C; Bales KR; am Ende CW; Fish BA; Green ME; Kauffman GW; Lira R; Mullins PB; Navaratnam T; Sakya SM; Stiff CM; Tran TP; Vetelino BC; Xie L; Zhang L; Pustilnik LR; Wood KM; O'Donnell CJ
Bioorg Med Chem Lett; 2012 Apr; 22(8):2906-11. PubMed ID: 22429469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
